




Panacea: Enhancing Graph Learning with Multimodal Semantics for Drug Repositioning


**Zijun Dou¹, Yun Zhang, Baokun Zhang, Lingxiao Li,
Xiaoyue Feng, Renchu Guan, Xiaosong Han**

1. Presenter. Email: douzijunabc@gmail.com

Outline




Background



Design




Experiment



Conclusion


Outline




Background



Design



Experiment



Conclusion

Modern Drug Development




Modern drug development is a **multistage, high-risk process** of discovering and testing new molecules to achieve regulatory approval for therapeutic use

The Problem



- **Time-Consuming:** 10-15 years
- **Costly:** Over \$2 billion
- **High Failure Rate:** Over 90%

Drug Repositioning




The Role of AI

- Computational approaches are crucial for systematically and efficiently identifying high-potential drug repositioning candidates from vast biomedical data

The Opportunity

- **A New Paradigm:** Drug Repositioning
- **Definition:** Identifying new therapeutic uses for existing, approved drugs ("old drugs, new tricks")
- **Key Advantages:**
 - **Reduced Time & Cost:** Bypasses early-stage discovery and pre-clinical testing
 - **Lower Risk:** Safety and pharmacokinetic profiles are already well-established

Problem Formulation




Formulation as a Graph


- **Model:** A general biomedical graph
 - Nodes represent the core entities, such as drugs and diseases
 - Edges denote known drug-drug, drug-disease, and disease-disease interactions
- **Task:** Predicting potential new drug-disease associations
- Existing approaches mainly rely on **Graph Neural Networks (GNNs)** for representation learning

Related Works

Taxonomy of graph-based learning methods for drug repositioning



Limitations



Data Sparsity

- i The scarcity of high-quality labeled drug-disease associations leads to weak input representations and undermines the foundation for effective graph learning




Over-smoothing

- i Multi-layer message passing in GNNs leads to **indistinguishable node representations**, severely degrading model performance and generalization.

Our Goal

Our goal is to design an automated ***multimodal semantics-enhanced*** graph learning framework for drug repositioning



- Collect multimodal biomedical data: including drug, disease, and biomedical graphs
- Encode modality-specific information: generate unified embeddings for each modality
- Perform graph learning: capture structural and semantic relationships
- Predict novel drug-disease associations: enable automated drug repositioning

Key Challenges

Limitation 1
Data sparsity



Challenge 1

Multimodal semantic integration: How to effectively integrate heterogeneous biomedical modalities, such as biomedical graphs, molecular structures, and textual symptoms descriptions


Limitation 2
Over-smoothing



Challenge 2

Structural expressiveness under sparse inputs: How to preserve representation diversity and maintain expressive power as the number of graph layers increase


Outline



Background



Design




Experiment



Conclusion

Model Overview



Panacea is an automated **multimodal** semantics-enhanced **graph learning** framework for **drug repositioning**. It mainly includes (a) Multimodal Semantic Modeling, (b) Hierarchical Graph Learning, and (c) Drug Repositioning


Multimodal Semantic Modeling

Modality Data

- Biomedical graphs (drug, disease)
- Drug SMILES strings from PubChem
- Disease symptom descriptions from OMIM

Encoding

- Graph Edge → Edge encoder → Topology embedding
- SMILES → MolBERT → Structure-aware embedding
- Symptom Text → ChatGPT-4o → compress and standardize → Qwen2.5-7B-Instruct → Textual embedding



Multimodal Semantic Modeling

Prompt Case

- **Motivation:** Clinical symptom descriptions exhibit varying lengths and inconsistent quality
- **Example:** Overly long descriptions may contain redundant or irrelevant information
- **Method:** Leverage ChatGPT-4o to compress and standardize the symptom texts, ensuring semantic consistency and uniform length distribution

Example

Input:

INHERITANCE - Autosomal recessive GROWTH Height - Short stature HEAD & NECK Head - Microcephaly - Brachycephaly - Turribrachycephaly - Plagiocephaly (in some patients) - Wide fontanelles Face – Craniofacial dysplasia - Prominent forehead - Midface hypoplasia - ‘Fishlike’ facies - Choanal atresia or choanal stenosis - Micrognathia - Prognathism (in some patients) Ears - Low-set ears - Dysplastic ears (in some patients) - Posteriorly rotated ears (in some patients) - Protruding ears (in some patients) - Hearing loss, mixed (in some patients) Eyes - Exophthalmos - Downslanting palpebral fissures - Hypertelorism (in some patients) - Arched eyebrows (in some patients) Nose - Hypoplastic nose - Depressed nasal bridge Mouth - Gingival hyperplasia - Cleft palate - High palate - Small mouth - Wide mouth (in some patients) - Large protruding tongue Teeth - Abnormal teeth (in some patients) - Natal teeth (in some patients) - Small teeth (in some patients) - Enamel dysplasia (in some patients)

Prompt:




Please rewrite the clinical symptom description into a concise and standardized format suitable for structured clinical NLP tasks. Focus on key abnormal findings, remove redundancies, and maintain medical accuracy.

Refinement:

Autosomal recessive disorder characterized by short stature, craniofacial dysplasia, midface hypoplasia, microcephaly, low-set dysplastic ears, hearing loss, exophthalmos, cleft or high palate, wide fontanelles, and dental abnormalities.

Multimodal Semantic Modeling

Distribution Experiment




- Experiment result: After refinement, clinical description lengths are shortened and standardized to a more uniform length

Multimodal Semantic Modeling


Alignment and Fusion

- **Motivation:** Enable effective alignment and produce modality-compatible representations
- Introduce a lightweight **linear projection layer**, mapping the drug molecular embeddings into the latent space of textual modality
 - $H_q = W \cdot Z_q$
- Compute a **semantic-aware similarity** w_{ij} score using cosine similarity
- Obtain **adaptive edge embedding** by fusing structure- and semantics-aware components
 - $H_w = Z_w + \beta \cdot \text{MLP}(w_{ij})$




Hierarchical Graph Learning

- **Goal:** Captures higher-order dependencies and alleviates the over-smoothing problem
- **Method:** Employs a novel Graph Isomorphism Network with gated mechanisms and residual connections
- Builds **hierarchical receptive fields** across k-hop neighborhoods
- Progressively integrate structural signals from **near to distant** nodes, enhancing the representation capacity



Hierarchical Graph Learning


GIN Layer




- the message passing within each GIN layer proceeds in **three stages**
 - weighted neighborhood aggregation**, incorporating structure-aware and semantics-aware edge weights $\rightarrow \mathbf{a}_i^{(l)} = \sum_{j \in \mathcal{N}(i)} \mathbf{H}_w^{ij} \odot \mathbf{h}_j^{(l-1)}$
 - adaptive gating mechanism**, control the integration of newly aggregated information and the original semantics $\rightarrow \mathbf{g}_i^{(l)} = \sigma \left(\text{MLP} \left([\mathbf{a}_i^{(l)} \parallel \mathbf{h}_i^{(0)}] \right) \right), \mathbf{c}_i^{(l)} = \mathbf{c}_i^{(l-1)} + \mathbf{g}_i^{(l)}$
 - residual update**, compute the candidate representation $\rightarrow \mathbf{h}_i^{(l)} = \text{MLP} \left(\mathbf{a}_i^{(l)} \right) + (1 - \mathbf{c}_i^{(l)}) \odot \mathbf{h}_i^{(0)}$

Downstream Task: Drug Repositioning

- **Input:** Final drug and disease embeddings
- **Scoring:**
 - Dot-product
 - $s_{ij} = \mathbf{H}_q^{i'} \cdot \mathbf{H}_p^{j'} = \sum_{k=1}^d (\mathbf{H}_q^{i'})_k \cdot (\mathbf{H}_p^{j'})_k$
 - Sigmoid
 - $y_{ij} = \sigma(s_{ij}) = \frac{1}{1 + \exp(-s_{ij})}$
 - association probability
- **Loss:** Composite loss which jointly optimizes multimodal semantic modeling and hierarchical graph learning



Outline




Background



Design



Experiment



Conclusion

Research Questions



RQ1: Effectiveness of Drug Repositioning

Does Panacea achieve superior performance on drug repositioning compared to existing SOTA methods?



RQ2: Ablation Study

How effective are Panacea's core design components?



RQ3: Multimodal Representation Analysis

What does Panacea learn through multimodal graph representation learning?



RQ4: Over-smoothing Mitigation Verification

Does Panacea effectively mitigate the over-smoothing issue commonly observed in graph learning?



RQ5: Hyperparameter Robustness Evaluation

How do hyperparameter configuration affect the performance of Panacea?



RQ6: Case Study

Can Panacea discover clinically relevant drug-disease associations supported by literature evidence?

Experiment Settings

Baselines

- Graph representation learning
 - DRHGCN, SCMFDD, SCPMF
- Graph propagation learning
 - HDGAT
- Graph heterogeneous learning
 - AutoDR, HNDR

Datasets

Dataset	No.of drugs	No.of diseases	No.of associations	Sparsity
Fdataset [8]	593	313	1933	1.04%
Cdataset [9]	663	409	2352	0.87%
LRSSL [10]	763	681	3051	0.59%

Metrics

- **AUROC, AUPRC**: assess the model's overall ranking performance
- **F1-score, Precision, Recall**: measure the prediction reliability at different decision thresholds
- For all metrics, higher values indicate better performance

Results




RQ1: Effectiveness of Drug Repositioning

Dataset	Metric	Model						Ours
		HDGAT	DRHGCN	SCPMF	SCMFDD	HNRD	AutoDR	
Fdataset	F1-score	0.493 ± 0.004	0.516 ± 0.007	0.418 ± 0.006	0.364 ± 0.004	0.469 ± 0.008	0.502 ± 0.005	0.518 ± 0.006
	Precision	0.734 ± 0.006	0.690 ± 0.008	0.556 ± 0.008	0.515 ± 0.004	0.701 ± 0.008	0.667 ± 0.007	0.788 ± 0.007
	Recall	0.371 ± 0.006	0.404 ± 0.006	0.335 ± 0.007	0.282 ± 0.003	0.352 ± 0.011	0.402 ± 0.006	0.386 ± 0.006
	AUROC	0.911 ± 0.001	0.944 ± 0.002	0.893 ± 0.001	0.776 ± 0.001	0.881 ± 0.004	0.943 ± 0.002	0.943 ± 0.001
	AUPRC	0.303 ± 0.002	0.543 ± 0.006	0.349 ± 0.006	0.005 ± 0.000	0.350 ± 0.006	0.539 ± 0.008	0.562 ± 0.005
Cdataset	F1-score	0.572 ± 0.007	0.624 ± 0.006	0.551 ± 0.007	0.466 ± 0.003	0.557 ± 0.007	0.564 ± 0.005	0.638 ± 0.006
	Precision	0.634 ± 0.006	0.730 ± 0.007	0.572 ± 0.007	0.608 ± 0.005	0.597 ± 0.008	0.803 ± 0.007	0.726 ± 0.007
	Recall	0.521 ± 0.006	0.545 ± 0.007	0.531 ± 0.006	0.378 ± 0.004	0.521 ± 0.007	0.435 ± 0.005	0.553 ± 0.006
	AUROC	0.925 ± 0.002	0.960 ± 0.001	0.913 ± 0.002	0.793 ± 0.001	0.913 ± 0.002	0.916 ± 0.001	0.963 ± 0.001
	AUPRC	0.337 ± 0.002	0.640 ± 0.005	0.423 ± 0.004	0.005 ± 0.000	0.423 ± 0.004	0.625 ± 0.004	0.640 ± 0.004
LRSSL	F1-score	0.422 ± 0.015	0.450 ± 0.015	0.403 ± 0.017	0.286 ± 0.008	0.412 ± 0.020	0.451 ± 0.015	0.456 ± 0.017
	Precision	0.389 ± 0.012	0.410 ± 0.017	0.352 ± 0.017	0.251 ± 0.007	0.366 ± 0.018	0.402 ± 0.015	0.426 ± 0.017
	Recall	0.462 ± 0.009	0.497 ± 0.010	0.472 ± 0.007	0.332 ± 0.002	0.472 ± 0.009	0.515 ± 0.010	0.497 ± 0.007
	AUROC	0.928 ± 0.002	0.957 ± 0.001	0.895 ± 0.001	0.768 ± 0.001	0.849 ± 0.003	0.948 ± 0.002	0.959 ± 0.001
	AUPRC	0.359 ± 0.002	0.417 ± 0.005	0.271 ± 0.002	0.004 ± 0.000	0.428 ± 0.004	0.417 ± 0.003	0.432 ± 0.002
Average	F1-score	0.422	0.530	0.457	0.372	0.479	0.506	0.537
	Precision	0.389	0.610	0.493	0.458	0.554	0.624	0.647
	Recall	0.462	0.482	0.446	0.330	0.448	0.451	0.479
	AUROC	0.921	0.954	0.900	0.779	0.881	0.936	0.955
	AUPRC	0.333	0.533	0.348	0.005	0.400	0.527	0.545
1 st Count		0	4	0	0	0	2	15

Finding: Panacea achieves **the highest score** in all 15 dataset-metric combinations

Results

RQ2: Ablation Study




- **w/o HGL** → moderate overall drop (up to **-6.4% AUPRC**)
- **w/o MSM/ Refinement** → large impact ($\sim 11\% \downarrow F1$), proving multimodal priors are useful
- **w/o RC** → severe precision degradation on sparse datasets (**-18.3% F1**)

Finding: All modules contribute to performance. **MSM** and **RC** are most critical, reducing **AUROC** by up to **5.5%** and **F1** by **18.3%** when removed

Results

RQ3: Multimodal Representation Analysis




- Left: before hierarchical graph learning → **scattered & mixed embeddings**
- Right: after hierarchical graph learning → **clearer clustering and semantic separation**

Finding: Panacea transforms heterogenous multimodal inputs into **well-structured and semantically meaningful embeddings**, enabling more accurate drug-disease association modeling

Results

RQ4: Over-smoothing Mitigation Verification




Average cosine similarity
between node embeddings
at adjacent hops (lower =
less over-smoothing)


Finding: Panacea effectively **alleviates over-smoothing**, maintaining expressive node representations across deep layers

Results

RQ5: Hyperparameter Robustness Evaluation



(a) Embedding Size



(b) Adaptive Weight

Finding: Panacea remains stable across different **embedding sizes** and **adaptive weights**, demonstrating strong robustness to hyperparameter variations

Results


RQ6: Case Study

- **Goal:** Validate whether predicted drug-disease associations are clinically meaningful and supported by literature
- **Takeaway:** Predicted associations are **clinically relevant and literature-supported**, demonstrating the practical utility of Panacea in real-world drug repositioning

TABLE IV: Representative drug-disease predictions made by Panacea and supporting evidences from the literature.

Diseases	DrugBankIDs	Candidate Drugs	Evidences
BC	DB01229	Paclitaxel	[27]
AD	DB00747	Scopolamine	[28]
PD	DB00246	Ziprasidone	[29]
BC	DB00755	Tretinoin	[30]
PNE	DB00321	Amitriptyline	[31]


Outline




Background



Design



Experiment



Conclusion

Conclusion

- **Panacea Framework:** We propose Panacea, a *multimodal semantics-enhanced graph learning* framework for drug repositioning
- **Multimodal Integration:** Panacea integrates *biomedical graphs*, *drug molecular structures*, and *disease symptom descriptions*, aligned via modality-specific encoders and a learnable fusion layer
- **Hierarchical Graph Learning:** A *gated hierarchical GIN* with residual connections enhances representation capacity and mitigates over-smoothing
- **Performance Gains:** Panacea achieves state-of-the-art results across three benchmark datasets, with consistent improvements in *F1*, *AUROC*, and *AUPRC*, particularly under *high data sparsity*
- **Future Work:** We plan to explore *fine-grained semantic alignment* and extend Panacea to broader biomedical association prediction tasks



Thank You!

Q & A

Panacea: Enhancing Graph Learning with Multimodal Semantics for Drug Repositioning